inhaled!prostacyclins!in! pediatric!patients
TRANSCRIPT
!
! !
!
!
!
!
!
!
!
INHALED!PROSTACYCLINS!IN!
PEDIATRIC!PATIENTS:!!!!!!!!!!!!!!!!!!!!!!!
THE!NEW!NITRIC!OXIDE?!!
!
September!11th
,!2015!
University!of!Texas!at!Austin!!
!
! !
!
!
Molly!McNaull,!PharmD!
PGYO1!Pharmacy!Resident!
Seton!Healthcare!Family!!
!!
!
9/11/15%
1%
Inhaled Prostacyclins in Pediatric Patients: The New Nitric Oxide?
September%11th,%2015%%University%of%Texas%at%Aus>n%% Molly%McNaull,%PharmD%PGYG1%Pharmacy%Resident%Seton%Healthcare%Family%%
Conflict of Interest
• No%conflicts%of%interest%to%disclose%%
2%
Objectives
• Review disease states in which inhaled nitric oxide and inhaled prostacyclins are commonly used
• Compare and contrast inhaled nitric oxide with
prostacyclin therapies
• Evaluate the literature available on inhaled nitric oxide and prostacyclin use in pediatric patients
• Determine if inhaled epoprostenol may be used in place of inhaled nitric oxide
3%
Pulmonary Hypertension (PH)
4%
PH Definition
• Eleva>on%of%mean%pulmonary%artery%pressure%(PAPm)%▫ PAPm%≥%25%mmHg%
• Due%to%various%causes%%▫ Pulmonary%arterial%hypertension%%▫ Persistent%pulmonary%hypertension%of%the%newborn%▫ Acute%lung%injury%▫ Acute%respiratory%distress%syndrome%
Galiè%N%et%al.%Eur$Heart$J.%2015;%pii:%ehv317.$
5%
Pulmonary Arterial Hypertension (PAH)
6%
9/11/15%
2%
PAH Background • Vascular%prolifera>on%and%remodeling%of%pulmonary%arterioles%!%pulmonary%vascular%resistance%(PVR)%%
• Defini>on%▫ PAPm%≥%25%mmHg%▫ PVR%>%3%Wood%units%▫ PAWP%≤%15%mmHg%
• Median%survival%for%idiopathic%PAH%%▫ Prior%to%synthe>c%prostacyclin:%%2.8%years%%▫ Now:%%>%7%years%%
Galiè%N%et%al.%Eur$Heart$J.%2015;%pii:%ehv317.%Benza%RL%et%al.%Chest.%2012;142(2):448G56.%
7%
PAH Pathophysiology
hep://circresearch.com/gallery/tag/pulmonaryGhypertension/%
8%
Types of PAH • Idiopathic%or%familial%(IPAH%or%FPAH)%%• Common%comorbidi>es%▫ Congenital%heart%disease%(CHD)%%▫ Chronic%lung%disease%▫ Connec>ve%>ssue%disease%▫ Liver%disease%
Ivy%et%al.%J$Am$Coll$Cardiol.2013;D117G26.%%
9%
Persistent Pulmonary Hypertension of the Newborn (PPHN)
10%
PPHN Background
• Failure%of%PVR%to%decrease%aher%birth%
• Presenta>on%%▫ Within%12%hours%of%birth%%▫ Cyanosis%▫ Acidosis%▫ Hypotension%%
• Mortality%rate%of%10%%%
% Bendapudi%P%et%al.%Paediatr$Respir$Rev.%2015;16(3):157G61.$
11%
Normal Fetal Circulation • Low%SVR%
• Elevated%PVR%
• Presence%of%shunts%▫ Ductus%arteriousus%%▫ Foramen%ovale%
• Vasoconstric>on%
• Low%produc>on%of%vasodilators%▫ Nitric%oxide%%▫ Prostacyclin%%
Steinhorn%%RH.%Pediatr$Crit$Care$Med.%2010;11(2S):79G84.%TeixeiraGMendonca%C%and%HenriquesGCoelho%T.%Rev$Port$Cardiol.$2013;32(12):1005G12.%
12%
9/11/15%
3%
Holloway%B%et%al.$URMC$Health$Encyclopedia%2015.%
13%
Normal Cardiopulmonary Transition at Birth
• Fetal%prepara>on%▫ Increased%expression%of%nitric%oxide%synthases%▫ Prostacyclin%pathway%
• Rapid%fall%in%PVR%and%PAP%
• 10Gfold%rise%in%pulmonary%blood%flow%
• Signals%for%transi>on%▫ Mechanical%distension%of%the%lung%▫ Decrease%in%CO2%tension%in%lungs%▫ Increase%in%O2%tension%in%lungs%
Steinhorn%%RH.%Pediatr$Crit$Care$Med.%2010;11(2S):79G84.%
14%
Causes of PPHN • Maladapta>on%of%pulmonary%vascular%bed%▫ Idiopathic%PPHN%
• Hypoplas>c%vasculature%▫ Congenital%diaphragma>c%hernia%%
• Constricted%pulmonary%vasculature%▫ Meconium%aspira>on%syndrome%▫ Pneumonia%%▫ Respiratory%distress%syndrome%%
%Steinhorn%%RH.%Pediatr$Crit$Care$Med.%2010;11(2S):79G84.%
15%
Acute Lung Injury (ALI)
16%
ALI and ARDS Definition • ALI%▫ Acute%hypoxia%%▫ PaO2/FiO2≤%300%mmHg%
• ARDS%%▫ Severe%hypoxemic%respiratory%failure%%! PaO2/FiO2≤%200%mmHg%on%PEEP%≥%5cm%H2O%▫ Bilateral%infiltra>on%on%chest%imaging%%▫ Inflammatory%injury%to%alveolar%capillary%barrier%
Han%S%and%Mallampalli%RK.%%J$Immunol.%2015;194:855G60.%
17%
ALI Risk Factors
Ware%LB%and%Maehay%MA.%N$Engl$J$Med.%2000;342(18):1334G49.%
Primary'Lung'Injury' Secondary'Lung'Injury''
Pneumonia% Sepsis%
Aspira>on% Mul>ple%trauma%
Pulmonary%contusion% Cardiopulmonary%bypass%
Fat,%amnio>c%fluid%or%air%emboli%
Drug%overdose%%
NearGdrowning%or%inhala>on%injury%
Acute%pancrea>>s%
Reperfusion%pulmonary%edema%
Transfusion%of%blood%products%%
18%
9/11/15%
4%
ARDS Pathophysiology
Han%S%and%Mallampalli%RK.%J$Immunol.%2015;194:855G60.%
19%
ARDS Pathophysiology
Han%S%and%Mallampalli%RK.%J$Immunol.%2015;194:855G60.%
20%
ARDS Pathophysiology
hep://samadimd.com/yourGcare/acuteGrespiratoryGdistressGsyndrome%
21%
PH Treatment Strategies
• Reverse%underlying%cause%%
• Suppor>ve%therapy%%▫ Mechanical%ven>la>on%%▫ Prone%posi>oning%%▫ Inhaled%nitric%oxide%(iNO)%%▫ Surfactant%replacement%for%neonates%
• Extracorporeal%membrane%oxygena>on%(ECMO)%
Curr$Probl$Pediatr$Adolesc$Health$Care$2013;%43:278G284%
22%
Pharmacotherapy
23%
Inhaled Nitric Oxide (iNO) Product' INOmax'gas'for'inhala;on'
Mechanism%of%ac>on%
Vascular%smooth%muscle%relaxa>on%!%pulmonary%vasodila>on%!%increase%in%PaO2%
Pediatric%dosing%% 1G40%ppm%
Adverse%events% Hypotension,%methemoglobinemia,%pulmonary%edema,%hypoxemia%
Cost% $100G200%per%hour%%
Ichinose%F%et%al.%CirculaAon.%2004;%109:%3106G11.%%Pierce%CM%et%al.%BMJ.$2002;325(7359):336.%Torbic%H%et%al.%J$Crit$Care.$2013;28:844G8.%
INOmax%[package%insert]%INO%Therapeu>cs.%2013.%%%
24%
9/11/15%
5%
iNO Mechanism
Berne%RM.%Berne$&$Levy$Physiology.$2008.$Philadelphia,%PA:%Mosby/Elsvier.%%
25%
iNO Adverse Effects
BinGNun%A%and%Schreiber%MD.%J$Perinatol.$2008;%28:S84G92.%
26%
Why Not iNO? • Cost%%• Toxicity%and%adverse%events%• Inconsistent%pa>ent%response%• Lack%of%postopera>ve%mortality%benefit%for%children%with%PH%and%CHD%
• Transient%benefits%seen%in%ARDS%in%adults%▫ Poor%methodology%in%pediatric%studies%
• Lack%of%data%for%preterm%neonates%%
Bizzarro%M%et%al.%Cochrane$Database$Syst$Rev.$2014;7:CD005055%Adhikari%NK%et%al.%BMJ.2007;334:779.%
Bronicki%RA%et%al.%J$Pediatr.2015;166:365G9.%
27%
iNO Literature Cita;on' Pa;ent'
Popula;on'Interven;on' Findings''
Miller%OI%et%al.%Lancet.%2000;356%(9240):1464G69.%
Infants%(n=124)%%!%correc>ve%surgery%for%CHD%
iNO%10ppm%or%Placebo%
• Fewer%PHTC%• Shorter%>me%to%extuba>on%• No%toxic%effects%• No%difference%in%mortality%
Bronicki%RA%et%al.%%J$Pediatr.2015;%166:365G9.%
Children%with%ARDS%(n=55)%%
iNO%5ppm%%or%%Placebo%%
• Improved%OI%at%12%h,%no%longer%at%24%h%
• Reduced%mechanical%ven>la>on%%• ECMOGfree%survival%%• No%difference%in%mortality%
Roberts%JD%Jr%et%al.%N$Engl$J$Med.%1997;336(9):605G10.%$
FullGterm%infants%with%severe%hypoxemia%and%PPHN%(n=58)%
iNO%80ppm%or%Placebo%
• Doubled%systemic%oxygena>on%in%53%%of%iNO%group%
• ECMOGfree%survival%• No%difference%in%mortality%or%AE%
28%
Prostacyclins
29%
Prostacyclin (PGI2) Mechanism • Ac>va>on%of%adenylate%cyclase%▫ Vasodila>on%of%vascular%beds%
• Decreased%thrombogenesis%and%platelet%aggrega>on%▫ ARDS%%
Berne%RM.%Berne$&$Levy$Physiology.$2008.$Philadelphia,%PA:%Mosby/Elsvier.%%
30%
9/11/15%
6%
Generic' Dosing'' Adverse'Events' HalfElife' Cost*'
Iloprost' Inh:$2.5G7.5%mcg/dose%5G9%>mes/day%%
Cough,%flushing,%headache,%nausea,%hypotension,%bleeding,%bronchospasm%%
20G30%minutes%
$80G433%
Trepros;nil' Inh:$$3%to%9%breaths%(6%mcg/%breath)%4%>mes/%day%IV/subcut:$$50G70ng/kg/min%
Inh:$hypotension,%bleeding,%cough,%headache,%nausea,%flushing,%syncope%%IV/subcut:$infusion%site%reac>on,%diarrhea,%jaw%pain%
4%hours% Inh:$$$24G73%$IV/subcut:$$$64%%
Epoprostenol'' IV:$2%ng/kg/min,%>trate%q30%min%by%2ng/kg/min%%(max=%120ng/kg/min)%$
Infusion%site%reac>on,%flushing,%headache,%hypotension,%agita>on,%chest%pain,%tachycardia,%dizziness,%arthralgia%
6%minutes%
$10G20%
%Ventavis®%[prescribing%informa>on].%Actellion%Pharmaceu>cals%US,%Inc.%2013.%Remodulin®%[prescribing%informa>on].%United%Therapeu>cs%Corp.%2014.%
Flolan®%[prescribing%informa>on]%GlaxoSmithKline.%2015.%
*Es>mated%cost%per%day%for%a%10%kg%pa>ent%
PGI2 Medications
31%
Why Inhaled Prostacyclins?
Complica;ons'of'Parenteral'
• Hypotension%%• Nausea%%• Dizziness%• Myalgias%%• FluGlike%syndrome%• Bleeding%%
• Direct%administra>on%allows%for%selec>vity%%
• Decreased%rates%of%adverse%events%%
Benefits'of'Inhaled''
Flolan®%[prescribing%informa>on]%GlaxoSmithKline.%2015.%Torbic%H%et%al.%J$Crit$Care.$2013;28:844G8.%
Dahlem%P%et%al.%Crit$Care$Med.$2004;32(4):1055G60.%
32%
Evidence for Inhaled Iloprost
%%%
Vorhies%EE.%Pediatr%Cardiol.%2014;%35(8):%1337G43.%%Ivy%DD%et%al.%%J$Am$Coll$Cardiol.$2008;51:161G9.%
Limsuwan%A%et%al.%%Int%J$Cardiol.$2008;129(3):333G8.%
Ivy%
• Transi>on%from%IV%prostanoids%%• Sustained%func>onal%improvement%in%PAH%
Vorhies%• Alterna>ve%to%iNO%for%postopera>ve%PH%in%CHD%%%
AE%• Lower%airway%reac>vity%
33%
Evidence for Inhaled Treprostinil
Takatsuki%et%al.,%Pediatr$Cardiol.$2013;%34:%1006G12.%Krishnan%U%et%al.,%Am$J$Cardiol.$2012;%110:%1704G9.%
McIntyre%CM%et%al.%Pulm$Circ.2013;3(4):862G9.%
Takatsuki%• Studied%for%use%in%AVT%
Krishnan%
• WHO%func>onal%class%improvement%• Exercise%capacity%improvement%%
AE%
• Well%tolerated%in%infants%• Cough,%hypotension%%
34%
Epoprostenol: The Other Inhaled Prostacyclin
• Con>nuous%infusion%via%nebulizer%%▫ Recons>tute%and%dilute%IV%solu>on%%
• Pediatric%dosing:%%%▫ Ini>al:%10G50%ng/kg/min%%! Titrate%by%10%ng/kg/min%q30%min%%! Max:%100G150%ng/kg/min%
Torbic%H%et%al.%J$Crit$Care.$2013;28:844G8.%
35%
Inhaled Epoprostenol (iEPO) in Adult Patients
$Preston%IR%et%al.%Pulm$Circ$2013;%3(1):%68G73.%
De%Wet%CJ%et%al.%J$Thorac$Cardiovasc$Surg$2004;127(4):1058G67.$
Preston%• Vasodilator%effects%in%PH%comparable%to%iNO%
De%Wet%• PH,%RV%dysfunc>on,%refractory%hypoxemia%• Decreased%PAPm%compared%to%baseline%%
AE%• No%significant%AE%
36%
9/11/15%
7%
Could inhaled epoprostenol replace inhaled nitric
oxide in the pediatric population with pulmonary
hypertension?
CLINICAL QUESTION
37%
CHD%
Adult%ALI%
ALI%PPHN%
Literature Review
38%
Carroll'CL'et'al.'J"Card"Surg.'2005;20:436E9.'Title' Inhaled$prostacyclin$following$surgical$repair$of$congenital$heart$
disease$–$a$pilot$study$
Objec;ve'' To%examine%the%effect%of%iEPO%in%the%immediate%postopera>ve%period%in%children%with%congenital%heart%disease%
Popula;on' Children%with%CHD%undergoing%intracardiac%surgery%with%preopera>ve%PH%(n=6)%%
Methods' Prospec>ve,%preliminary%pilot%study%%iEPO%administered%postopera>vely%%Hemodynamics%at%baseline,%aher%iEPO,%and%aher%discon>nua>on%
Results' • Reduced%PAPm%from%25%mmHg%to%21%mmHg%(p%<%0.01)%• ImprovedPaO2/FiO2%ra>o%from%275%to%433%(p=0.01)%%• No%change%in%PVR/SVR%%
Conclusions' iEPO%reduced%PAP%and%improved%oxygena>on%Children%with%CHD%and%PH%may%benefit%from%iEPO%Further%inves>ga>on%in%a%large%group%is%warranted%%
39%
Torbic H, Szumita PM, Anger KE et al. Inhaled epoprostenol vs inhaled nitric oxide for hypoxemia in critically ill patients. J Crit Care 2013;28:844-8.
40%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Objec;ve''
• To%compare%efficacy,%safety,%and%cost%outcomes%in%pa>ents%who%have%received%either%iEPO%or%iNO%for%hypoxic%respiratory%failure%
Popula;on'
• ADULTS%(n=105)%mechanically%ven>lated%and%receiving%iEPO%or%iNO%for%improvement%in%oxygena>on%
Study'Design'
• Retrospec>ve,%singleGcenter%analysis%%
Methods'
• Aher%failing%maximal%conven>onal%therapy,%pa>ents%were%started%on%pulmonary%vasodilator%
• Dosing%• iNO:%1G80%ppm%%• iEPO:%10G50%ng/kg/min%
41%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Results'
42%
See%Appendix,%page%2%
9/11/15%
8%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Primary'Outcome''
• Change%in%PaO2/FiO2%ra>o%aher%1%hour%of%vasodilator%therapy%%
Secondary'Outcomes'
• ICU%length%of%stay%• Hospital%length%of%stay%• Dura>on%of%therapy%• Dura>on%of%mechanical%ven>la>on%• Incidence%of%adverse%events%• Cost%
43%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Results'
Primary%Outcome%%
Change%in%PaO2/FiO2%ra>o%aher%1%hour:%%no%difference%(p=0.36)%• iNO%increase%by%%%%%%%%%%%%%%%%%%%%%%%%%%20.58%±%91.54%• iEPO%increase%by%%%%%%%%%%%%%%%%%%%%%%%%33.04%±%36.19%
44%
See%Appendix,%page%2%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Results'
45%
See%Appendix,%page%2%
Torbic'H'et'al.'J"Crit"Care."2013;28:844E8."Conclusions'
• No%detectable%differences%between%iNO%and%iEPO%%• PaO2/FiO2%• Clinical%outcomes%%• Adverse%events%
• iNO%is%associated%with%greater%drug%expenditure%
Limita;ons'
• Retrospec>ve%study%%• Single%academic%medical%center%• Several%indica>ons%for%use%%• Differences%in%baseline%characteris>cs%between%groups%
• Weight%%• Baseline%PaO2/FiO2%
Applica;on'
In$adults$with$ARDS$• iEPO$appears$to$be$as$safe$and$effecAve$as$iNO$at$a$substanAally$lower$cost$$…Does$this$hold$true$for$pediatric$paAents?$$$
46%
Dahlem P, van Aalderen WM, de Neef M et al. Randomized controlled trial of aerosolized prostacyclin therapy in children with acute lung injury. Crit Care Med 2004;32:1055-60.
47%
Dahlem'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Objec;ve''
To%inves>gate%whether%iEPO%improves%oxygena>on%in%children%with%ALI%
Popula;on'
Children%(n=14)%with%acute%lung%injury%requiring%mechanical%ven>la>on%%• PaO2/FiO2%ra>o%≤%300%torr%• Bilateral%infiltrates%on%chest%radiograph%%Exclusion:%%%• Thrombocytopenia%%• aPTT%>%43%seconds%• Intracranial%hemorrhage%%• CHD%
Study'Design'
• DoubleGblind,%placeboGcontrolled%%
48%
9/11/15%
9%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Methods'
• Crossover%randomiza>on%• Group%1:%'iEPO,%then%normal%saline%• Group%2:''normal%saline,%then%iEPO%
• Prostacyclin%dosing%• Stepwise%increments%(10,%20,%30,%40%and%50%ng/kg/min)%%
• Data%collec>on%• HR,%MAP,%ABG,%and%required%ven>lator%sezngs%%• Flow/volume%(F/V)%curves%in%9%of%14%pa>ents%
• Primary%outcome%• Oxygena>on%index%(OI)%
49%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Results'
50%
See%Appendix,%page%3%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Results'
Significant%improvement%in%OI%with%iEPO%at%30%ng/kg/min%compare%to%placebo%• Median%extent%of%improvement:%%26%%%
51%
See%Appendix,%page%4%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Results'
52%
See%Appendix,%page%3%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Results'
53%
See%Appendix,%page%4%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Results'
Adverse%effects%%• No%difference%seen%in%HR,%MAP,%or%FiO2%• No%bleeding%events%%• In%those%with%F/V%curves,%no%airway%hyperreac>vity%
54%
See%Appendix,%page%5%
9/11/15%
10%
Dahlem'P'et'al.'Crit"Care"Med."2004;32(4):1055E60.'Conclusions'
• iEPO%improves%oxygena>on%in%children%with%ALI%• Future%trials%are%needed%to%inves>gate%whether%this%therapy%will%improve%pa>ent%
outcomes%'
Limita;ons''
• Study%size%%• Designed%to%measure%surrogate%%• Unknown%background%therapy%%
Applica;on'
• iEPO$improves$OI$in$children$with$ALI$$• No$AE$observed$$• Unknown$effects$in$comparison$to$inhaled$nitric$oxide$• Unknown$impact$on$paAent$outcomes$$
55%
Brown AT, Gillespie JV, Miquel-Verges F et al. Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children. Pulm Circ 2012;2(1):61-6.
56%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Objec;ve''
• To%determine%the%efficacy%of%iEPO%for%treatment%of%acute%PH%in%pediatric%pa>ents%
Popula;on'
• Pa>ents%<%18%years%of%age%(n=20)%who%received%iEPO%for%at%least%1%hour%and%had%data%available%for%analysis%of%the%OI%before%and%during%treatment%%
Methods'
Retrospec>ve%chart%review%%• Other%pulmonary%vasodilators%used%%• Prepara>on:%%IV%epoprostenol%formula>on%was%recons>tuted%and%then%diluted%
for%nebuliza>on%%• Dosing:%%
• iEPO%at%50%ng/kg/min%nebulized%at%a%rate%of%8%ml/hr*%%%%%%%%*One%pa>ent%received%iEPO%intermieently%as%50%ng/kg%diluted%in%3%mL%of%diluent%%
57%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'
58%
See%Appendix,%page%6%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Primary'outcomes'
1) Propor>on%of%pa>ents%with%improved%OI%%2) Propor>on%of%pa>ents%whose%echocardiographic%data%(ECHO)%depicted%
improved%PAP%and/or%right%heart%mechanics%Secondary'outcomes'
• Need%for%ECMO%%• Deteriora>on%of%renal%or%liver%func>on%• Significant%drop%in%SBP%%• Worsening%respiratory%failure%%• Death%%
59%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Results'
Primary%outcomes%
1) Propor>on%of%pa>ents%with%improved%OI%%• Significant%decrease%in%OI%from%26.4%±%15.8%to%18.6%±%16.1%
(p=0.04)%%with%the%use%of%iEPO%
60%
See%Appendix,%page%6%
9/11/15%
11%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Subgroup'analysis''
61%
See%Appendix,%page%7%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Results'
Primary%outcomes%
2)%Pa>ents%with%ECHO%before%and%during%therapy%%
20%%
35%%
5%%
10%%
30%%
RV%Func>on%
Improvement%
No%change%
Worsening%
Insufficient%data%
ECMO%
62%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Results'
Safety%endpoints%
• AE%in%6%pa>ents%• 5%neonates%%• Most%common%AE%
• Hypotension%requiring%interven>on%• Respiratory%AE%
• Inconsistent%mean%airway%pressure%• NebulizerGven>lator%interface%
• Renal%func>on%• No%change%
• Deaths%%%• 4%(none%aeributed%to%iEPO)%
63%
Brown'AT'et'al.'Pulm"Circ.'2012;2(1):61E6.'Conclusions'
• Further%evidence%of%good%safety%profile%with%iEPO%in%pediatric%pa>ents%• iEPO%may%be%more%beneficial%in%neonates%than%in%older%children%• Iden>fies%the%need%for%a%large,%randomized%control%trial%on%the%use%of%iEPO%in%the%
general%pediatric%popula>on%Limita;ons'
• No%comparator%group%%• Sample%size%%
• Subgroups%%• Majority%were%neonates%Applica;on'
• iEPO$is$effecAve$in$improving$OI$in$neonates$with$PPHN$• Efficacy$of$iEPO$in$children$with$ARDS$or$cardiac$abnormaliAes$cannot$be$
determined$$
64%
iNO Summary • Standard%of%care%acute%exacerba>ons%of%PH%%▫ Improves%oxygena>on%%▫ Increases%ECMOGfree%survival%in%ARDS%and%PPHN%%▫ Despite%inconclusive%results%on%pa>ent%outcomes%
• Disadvantages%of%using%iNO%▫ Cost%▫ Risk%of%toxicity%%
65%
iEPO Conclusions • Dosing%%▫ 30%ng/kg/min%nebulized%con>nuously%%
• In%comparison%with%iNO%▫ Decreased%cost%to%pa>ent%%▫ Similar%improvements%in%PAPm%and%oxygena>on%
• Consider%iEPO%in%pediatric%pa>ents%with%hypoxemia%refractory%to%tradi>onal%therapies%▫ PPHN%%
• Further%research%needed%in%ARDS%and%CHD%▫ Larger%studies%▫ Mechanism%of%ac>on%!%theore>cal%benefit%%▫ Unknown%impact%on%outcomes%
66%
9/11/15%
12%
iEPO Summary • Epoprostenol%has%been%used%to%treat%acute%exacerba>ons%of%PH%
• Efficacy%of%iEPO%%▫ Lowers%PAP%and%improves%oxygena>on%in%CHD%postopera>vely%▫ Improves%oxygena>on%in%adults%with%ALI%▫ Improves%OI%of%neonates%with%PPHN%%
• No%significant%differences%in%safety%or%efficacy%%seen%between%iEPO%and%iNO%in%trials%
• Compared%to%parenteral%therapy,%iEPO%allows%for%selec>vity%▫ Minimizes%side%effects%
67%
Acknowledgements
• Carolyn%Ragsdale,%PharmD,%BCPS%• Lyndrick%Hamilton,%PharmD,%BCPS%• Ronda%Machen,%PharmD,%RD%%
68%
Inhaled Prostacyclins in Pediatric Patients: The New Nitric Oxide?
September%11th,%2015%%University%of%Texas%at%Aus>n%%%Molly%McNaull,%PharmD%PYGG1%Pharmacy%Resident%%Seton%Healthcare%Family%%%
APPENDIX(
! 1!
(
Table(1.!Acronyms!!
AE( Adverse!effects! IV Intravenous! ALI( Acute!lung!injury!! MAP( Mean!arterial!pressure!ARDS( Acute!respiratory!distress!syndrome! OI( Oxygenation!index!=!!!
([mean!airway!pressure!xFiO2!x100]/PaO2)!AVT Acute!vasodilator!testing PaO2( Arterial!pressure!of!oxygen!CHD! Congenital!heart!disease!! PAPm( Mean!pulmonary!arterial!pressure!ECHO(( Echocardiography!! PAWP! Pulmonary!artery!wedge!pressure!!ECMO! Extracorporeal!membrane!oxygenation!! PEEP( Positive!end!expiratory!pressure!FiO2 Fractional!inspired!oxygen PGI2! Prostacyclin!!FPAH( Familial!pulmonary!arterial!hypertension! PH Pulmonary!hypertension F/V(curve
FlowKvolume!curve PHTC! Pulmonary!hypertensive!crisis!
HR( Heart!rate!! PPHN Persistent!pulmonary!hypertension!of!the!newborn
ICU Intensive!care!unit! PVR( Pulmonary!vascular!resistance!iEPO( Inhaled!epoprostenol!! SBP( Systolic!blood!pressure!!Inh( Inhaled! SVR( Systemic!vascular!resistance!!iNO( Inhaled!nitric!oxide! WHO( World!Health!Organization!IPAH( Idiopathic!pulmonary!arterial!hypertension! ( !
( (
APPENDIX(
! 2!
(
! !
Torbic'H'et'al.'J"Crit"Care."2013;28:844F8.
APPENDIX(
! 3!
(
!
!
Dahlem'et'al.'Crit%Care%Med.%2004;32(4):1055F60.
APPENDIX(
! 4!
!
!
APPENDIX(
! 5!
!
! !
APPENDIX(
! 6!
!
!
Brown&AT&et&al.&Pulm%Circ.!2012;2(1):61F6.(
APPENDIX(
! 7!
!